Singapore, Feb 03, 2012: PAREXEL international, a leading global biopharmaceutical services provider, has entered into an agreement with ASAN Medical Center(AMC), based in Seoul, Korea. The alliance offers clinical trial sponsors based regionally and internationally with access to high quality clinical trial services throughout Asia, with a focus on early phase development.
"Through our collaboration with ASAN Medical Center we look forward to helping our clients take advantage of opportunities to support their Korea-based development and commercialization programs to benefit patients in Korea, throughout Asia, and around the world," said Dr Mark A Goldberg, MD, chief operating officer, PAREXEL International.
According to Dr Goldberg, "PAREXEL provides clients with patient access in key therapeutic areas for early phase development through our early phase units and global alliance network. Our relationship with the ASAN Medical Center affords us the opportunity to further extend this capability into Asia. With ASAN Medical Center's leadership in clinical trials, in-depth expertise, state-of-the art facilities, and a renowned network of hospitals, we believe our alliance will offer unique advantages to the Korean biopharmaceutical industry. We look forward to contributing to continued drug development growth in the region through shared learnings, technologies, and best practices."
"ASAN Medical Center is pleased to work with PAREXEL to help advance our research activities and develop meaningful innovations that contribute to health and longevity of patients in Korea and throughout Asia," said Mr Seong-Wook Park, MD PhD, president and CEO, ASAN Medical Center. "We look forward to collaborating with PAREXEL through our Department of Clinical Pharmacology and Therapeutics to promote, facilitate, and enhance the development and use of novel pharmacotherapeutics."
The AMC Clinical Trial Center, which opened in 2002, is a leading center in Korea that supports clinical trials conducted by ASAN Medical Center. It was designated as the Regional Clinical Trial Center by the Korean Ministry for Health, Welfare, and Family Affairs in 2006. The government's investment made it possible for the center to rapidly build infrastructure. The center provides high quality clinical trial services, and assures quality through its Quality Assurance Unit, sponsor audits, and inspections by regulatory authorities. The center incorporates the well-established Department of Clinical Pharmacology and Therapeutics.
PAREXEL is one of Asia's leading providers of biopharmaceutical services. The Company has had a presence in the Asia/Pacific region for over 16 years. PAREXEL has more than 2,800 employees and 21 offices throughout important industry centers in the region, including locations in Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, the Philippines,Singapore, South Korea, Taiwan, and Thailand. PAREXEL experts support biopharmaceutical companies in accessing diverse patient populations, navigating regulatory issues, identifying investigators, and ensuring data quality throughout the Asia/Pacific region.
Source:biospectrumasia.com